Tirzepatide, the first dual GIP/GLP-1 agonist, received US Food and Drug Administration (FDA) approval in 2023 (Zepbound ) after demonstrating superior efficacy over semaglutide, including 22% weight loss and enhanced glycaemic control [76,77,78]
Ideal Candidates Patients for whom diet and exercise alone have not effectively helped them lose weight may be good candidates for GLP-1
Brightens Pigmented Lips Kojic Acid and Niacinamide reduce melanin formation, fade discoloration, and even lip tone
Por eso, adems de impactar en la produccin de insulina del organismo, estos frmacos al imitar los efectos del GLP-1 -la hormona que el organismo libera en el intestino despus de comer y acta sobre los receptores del cerebro que controlan el apetito y la saciedad- propician una menor ingesta de alimentos y la consecuente prdida de peso
Gastrointestinal Research Studies Laboratory studies show BPC-157 exhibits gastroprotective effects through modulation of inflammatory pathways and enhancement of mucosal defense mechanisms in various GI research models